Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722773 | 0.81 | PARP1 (0.31) | PARP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL22699769 | 0.70 | KDM4E (0.41) | PARP1KDM4EALDH1A1GLAGAA | |
| SCHEMBL22433010 | 0.68 | MAPT (0.50) | QPCTHTTKDM4EALDH1A1 | |
| SCHEMBL24248631 | 0.68 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL22743385 | 0.67 | KDM4E (0.35) | QPCTKDM4EALDH1A1GLAGAA | |
| SCHEMBL19367490 | 0.67 | PDPK1 (0.33) | — | |
| SCHEMBL23682767 | 0.67 | ESR1 (0.38) | QPCTCA1CA2PARP1 | |
| SCHEMBL8047934 | 0.66 | KDM4E (0.36) | QPCTHTTPARP1KDM4EALDH1A1 | |
| SCHEMBL3578261 | 0.66 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL22725532 | 0.66 | KDM4E (0.31) | HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | QPCT 3202/4885CA1 4808/4885CA2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.